153567-11-4Relevant articles and documents
Delta opioid binding selectivity of 3-ether analogs of naltrindole
Coop, Andrew,Pinto, Julia,Wang, Lijuan,McCullough, Karen,Rothman, Richard B.,Dersch, Christine,Jacobson, Arthur E.,Rice, Kenner C.
, p. 3435 - 3438 (1999)
Masking of the 3-phenol of naltrindole as a range of ethers caused a decrease in binding affinity at all three opiate receptors (μ, κ, δ), however for the methyl ether, the reduction in affinity at both μ and κ was greater than at δ, thereby increasing δ
Discovery of novel delta opioid receptor (Dor) inverse agonist and irreversible (non-competitive) antagonists
Augelli-Szafran, Corinne E.,Moukha-Chafiq, Omar,Pathak, Vibha,Streicher, John M.,Tanguturi, Parthasaradhireddy,Zhang, Sixue
, (2021/11/27)
The delta opioid receptor (DOR) is a crucial receptor system that regulates pain, mood, anxiety, and similar mental states. DOR agonists, such as SNC80, and DOR-neutral antagonists, such as naltrindole, have been developed to investigate the DOR in vivo and as potential therapeutics for pain and depression. However, few inverse agonists and non-competitive/irreversible antagonists have been developed, and none are widely available. This leaves a gap in our pharmacological toolbox and limits our ability to investigate the biology of this receptor. Thus, we designed and synthesized the novel compounds SRI-9342 as an irreversible antagonist and SRI-45127/SRI-45128 as inverse agonists. Then, these compounds were evaluated in vitro for their binding affinity by radioligand binding and functional activity by35 S-GTPγS coupling and cAMP accumulation in cells expressing the human DOR. All three compounds demonstrated high binding affinity and selectivity at the DOR, and all three displayed their hypothesized molecular pharmacology of irreversible antagonism (SRI-9342) or inverse agonism (SRI-45127/SRI-45128). Together, these results demonstrate that we have designed new inverse agonists and irreversible antagonists of the DOR based on a novel chemical scaffold. These new compounds will provide new tools to investigate the biology of the DOR or even new potential therapeutics.
Preparation method for bromomethyl naltrexone
-
Paragraph 0025; 0035; 0066; 0067; 0068, (2017/01/19)
The invention specifically relates to a preparation method for bromomethyl naltrexone, belonging to the field of pharmaceutical chemicals. According to the invention, bromomethyl naltrexone is prepared from an intermediate, i.e., O-benzyl-N-bromomethyl na
An efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist
Martin, David J.,Fitzmorris, Paul E.,Deveau, Amy M.,Li, Bo,Ayestas, Mario,Sally, Ellicott J.,Dersch, Christina M.,Rothman, Richard B.
supporting information, p. 6801 - 6805,5 (2020/09/02)
In an effort to better understand the conformational preferences that inform the biological activity of naltrexone and related naltrexol derivatives, a new synthesis of the restricted analog 3-OBn-6β,14-epoxymorphinan 4 is described. 4 was synthesized starting from naltrexone in 50% overall yield, proceeding through the OBn-6α-triflate intermediate 8. Key steps to the synthesis include benzylation (96% yield), reduction (90% yield, α:β:3:2), followed by a one-pot triflation/displacement sequence (96% yield) to yield the desired bridged epoxy derivative 4. X-ray crystallographic analysis of intermediate 3-OBn-6α-naltrexol 7a supports population of the key boat conformation required for the epoxy ring closure. We also report that the 6β-mesylate 10-a high affinity opioid receptor ligand, the epimeric derivative of 11, and an analog of 12-functions as an inverse agonist at the mu opioid receptor using herkinorin pre-conditioned cells and an agonist at the kappa opioid receptor when evaluated in independent in vitro [ 35S]-GTP-γ-S assays.
